NCT06198309Recruiting
Risk Prediction Model for Exacerbating Phenotype in Patients With Chronic Obstructive Pulmonary Disease
A Risk-predictive Model for Frequent Acute Exacerbation Phenotype in Patients With Severe Chronic Obstructive Pulmonary Disease
Source: ClinicalTrials.gov · Last updated 10 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is planned to be conducted based on the cohort of patients with severe chronic obstructive pulmonary disease in our hospital. Based on gut microbiota, random forest was used to search for potential diagnostic biomarkers in patients with frequent acute exacerbation and controls with non frequent acute exacerbation; Construct a frequent acute exacerbation risk prediction model using random forest, support vector machine, and BP neural network models. The development of this study will provide valuable references for the clinical classification and prognosis evaluation of chronic obstructive pulmonary disease (COPD), and improve the health level of COPD patients by further searching for treatable targets.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 365 (estimated)
- First submitted
- 27 Dec 2023
- Start date
- 1 May 2023
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Li An
- Diseases
- COPD
- NCT number
- NCT06198309
What you commit to
- Study type: Observational
- Planned participants: 365
- From 1 May 2023 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Asthma, active pulmonary tuberculosis, interstitial pneumonia and severe Bronchiectasis
- Complicated with serious diseases (acute infection, diabetes, stroke, heart disease, liver and kidney dysfunction, cancer or autoimmune disease)
- History of chronic diarrhea or constipation
- History of Gastrointestinal Surgery
- No history of using oral hormones or traditional Chinese medicine in the past three months
Other
- Using probiotics or antibiotics within the past 4 weeks
- Pregnancy or lactation
Who the study is looking for
- Patients who meet the diagnostic criteria for COPD of the global initiative for chronic obstructive lung diseases (GOLD 2022) and GOLD grading Ⅲ - Ⅳ (FEV1/FVC\<70%, FEV1% predicted value ≤ 50% after Bronchiectasis)
- Age\>40 years old
- COPD stable for more than 4 weeks
- Short acting Bronchiectasis was not used within 24 hours before this experiment, long acting Bronchiectasis was not used within 48 hours, and glucocorticoids were not used throughout the body in the past month
- Patient informed and signed consent form
Age in the registry: 40 years to 85 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Chaoyang Hospital affiliated to Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.